216 related articles for article (PubMed ID: 31278869)
1. Next-generation sequencing of endoscopic ultrasound guided microbiopsies from pancreatic cystic neoplasms.
Vestrup Rift C; Melchior LC; Kovacevic B; Toxvaerd A; Klausen P; Karstensen JG; Kalaitzakis E; Storkholm J; Palnaes Hansen C; Vilmann P; Preuss Hasselby J
Histopathology; 2019 Nov; 75(5):767-771. PubMed ID: 31278869
[TBL] [Abstract][Full Text] [Related]
2. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
Singhi AD; McGrath K; Brand RE; Khalid A; Zeh HJ; Chennat JS; Fasanella KE; Papachristou GI; Slivka A; Bartlett DL; Dasyam AK; Hogg M; Lee KK; Marsh JW; Monaco SE; Ohori NP; Pingpank JF; Tsung A; Zureikat AH; Wald AI; Nikiforova MN
Gut; 2018 Dec; 67(12):2131-2141. PubMed ID: 28970292
[TBL] [Abstract][Full Text] [Related]
3. KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.
Schmitz D; Kazdal D; Allgäuer M; Trunk M; Vornhusen S; Nahm AM; Doll M; Weingärtner S; Endris V; Penzel R; Kirchner M; Brandt R; Neumann O; Sültmann H; Budczies J; Kienle P; Magdeburg R; Hetjens S; Schirmacher P; Bergmann F; Rudi J; Stenzinger A; Volckmar AL
Genes Chromosomes Cancer; 2021 Jul; 60(7):489-497. PubMed ID: 33686791
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
[TBL] [Abstract][Full Text] [Related]
5. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
[TBL] [Abstract][Full Text] [Related]
6. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
7. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
[TBL] [Abstract][Full Text] [Related]
8. Mutational Mosaics of Cell-Free DNA from Pancreatic Cyst Fluids.
Paziewska A; Polkowski M; Goryca K; Karczmarski J; Wiechowska-Kozlowska A; Dabrowska M; Mikula M; Ostrowski J
Dig Dis Sci; 2020 Aug; 65(8):2294-2301. PubMed ID: 31925676
[TBL] [Abstract][Full Text] [Related]
9. Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.
Volckmar AL; Endris V; Gaida MM; Leichsenring J; Stögbauer F; Allgäuer M; von Winterfeld M; Penzel R; Kirchner M; Brandt R; Neumann O; Sültmann H; Schirmacher P; Rudi J; Schmitz D; Stenzinger A
Genes Chromosomes Cancer; 2019 Jan; 58(1):3-11. PubMed ID: 30230086
[TBL] [Abstract][Full Text] [Related]
10. The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.
Basturk O; Tan M; Bhanot U; Allen P; Adsay V; Scott SN; Shah R; Berger MF; Askan G; Dikoglu E; Jobanputra V; Wrzeszczynski KO; Sigel C; Iacobuzio-Donahue C; Klimstra DS
Mod Pathol; 2016 Sep; 29(9):1058-69. PubMed ID: 27282351
[TBL] [Abstract][Full Text] [Related]
11. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data.
Singhi AD; Zeh HJ; Brand RE; Nikiforova MN; Chennat JS; Fasanella KE; Khalid A; Papachristou GI; Slivka A; Hogg M; Lee KK; Tsung A; Zureikat AH; McGrath K
Gastrointest Endosc; 2016 Jun; 83(6):1107-1117.e2. PubMed ID: 26709110
[TBL] [Abstract][Full Text] [Related]
12. The Use of Biomarkers in the Risk Stratification of Cystic Neoplasms.
Kaplan JH; Gonda TA
Gastrointest Endosc Clin N Am; 2018 Oct; 28(4):549-568. PubMed ID: 30241643
[TBL] [Abstract][Full Text] [Related]
13. Genomic profile concordance between pancreatic cyst fluid and neoplastic tissue.
Laquière AE; Lagarde A; Napoléon B; Bourdariat R; Atkinson A; Donatelli G; Pol B; Lecomte L; Curel L; Urena-Campos R; Helbert T; Valantin V; Mithieux F; Buono JP; Grandval P; Olschwang S
World J Gastroenterol; 2019 Sep; 25(36):5530-5542. PubMed ID: 31576098
[TBL] [Abstract][Full Text] [Related]
14. Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation.
Ren R; Krishna SG; Chen W; Frankel WL; Shen R; Zhao W; Avenarius MR; Garee J; Caruthers S; Jones D
Mod Pathol; 2021 Feb; 34(2):438-444. PubMed ID: 32792597
[TBL] [Abstract][Full Text] [Related]
15. Molecular Diagnostics in the Evaluation of Pancreatic Cysts.
Theisen BK; Wald AI; Singhi AD
Surg Pathol Clin; 2016 Sep; 9(3):441-56. PubMed ID: 27523971
[TBL] [Abstract][Full Text] [Related]
16. Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas.
Frampton AE; Stebbing J; Gall TM; Silver B; Jiao LR; Krell J
Expert Rev Mol Diagn; 2015 Mar; 15(3):325-8. PubMed ID: 25656048
[TBL] [Abstract][Full Text] [Related]
17. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts.
Nikiforova MN; Khalid A; Fasanella KE; McGrath KM; Brand RE; Chennat JS; Slivka A; Zeh HJ; Zureikat AH; Krasinskas AM; Ohori NP; Schoedel KE; Navina S; Mantha GS; Pai RK; Singhi AD
Mod Pathol; 2013 Nov; 26(11):1478-87. PubMed ID: 23743931
[TBL] [Abstract][Full Text] [Related]
18. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
[TBL] [Abstract][Full Text] [Related]
19. GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype.
Hata T; Mizuma M; Motoi F; Omori Y; Ishida M; Nakagawa K; Hayashi H; Morikawa T; Kamei T; Furukawa T; Unno M
Sci Rep; 2020 Oct; 10(1):17761. PubMed ID: 33082481
[TBL] [Abstract][Full Text] [Related]
20. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
